JAGUAR HEALTH, INC. Deferred Revenue, Current
JAGUAR HEALTH, INC. (JAGX) had Deferred Revenue, Current of $1.50 million as of 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2020-08-13
- 2020-06-30: Deferred Revenue, Current $1.50M.
- 2018-06-30: Deferred Revenue, Current $0.00.
- 2017-12-31: Deferred Revenue, Current $177.39K.
- 2017-09-30: Deferred Revenue, Current $224.45K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2020-06-30 | $1.50M 10-Q · filed 2020-08-13 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-13 |
| 2017-12-31 | $177.39K 10-Q · filed 2018-08-13 |
| 2017-09-30 | $224.45K 10-Q · filed 2017-11-20 |
| 2017-06-30 | $184.67K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $208.26K 10-Q/A · filed 2017-06-23 |
| 2016-12-31 | $224.45K 10-K · filed 2018-04-09 |
| 2016-09-30 | $246.24K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $262.67K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $279.06K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $251.94K 10-K · filed 2017-02-15 |
| 2015-09-30 | $336.71K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $373.59K 10-Q · filed 2015-08-13 |
| 2015-03-31 | $388.94K 10-Q · filed 2015-06-26 |
| 2014-12-31 | $23.80K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |